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Outline:
Capital, Knowledge and Power in the Global Pharmaceutical Business;
Structural Competition for Differential Accumulation
• Standard View on the Knowledge-Based Economy
• Power Theory of Capital
–Veblen’s Dichotomy Between Industry and Business
–Bichler and Nitzan’s Differential Accumulation
–The Concept of Structural Competition
• The Global Pharmaceutical Business
–Differential Accumulation in Pharmaceuticals
–A Surge in Innovation?
–Interpreting Breadth (Mergers and Acquisitions)
–Interpreting Depth (Marketing and IPR)
The Standard View on the Knowledge-Based
Economy
•«New Economy Thesis» (Cognitive Capitalism): Capital 
Accumulation relies more and more on new intangible 
sources of production and wealth, chiefly knowledge and 
intelligence. Accumulation regime based on creativity and
permanent innovation.
– Neoclassical Economics: New Growth Theories (Romer, 
Lucas, Mankiw)
– Marxist Theory and Regulation: Cognitive Capitalism or 
General Intellect (Negri, Virno, Gorz, Matisse-Issys)
– National Accounts: Intangible Assets (Lev, Sveiby)
–Sociological Theory: Networks and Access (Rifkin, Castells)
The Fatal Conceit in Economics;
Capital as means of production: Linking Business 
Earnings and Industrial Productivity
Actual Future
Business Income:    Investment ---------------Earnings
Industrial
Production: Production Goods----------Social Wealth
Myth of the Invisible Hand: By following its own interests (greater earnings), 
each individual will serve the public interest (production of social wealth) in the
best possible way. The income of capital is measured in the sphere of
production.
Power Theory of Capital
Veblen’s Contribution I: Dichotomy Business/Industry
(Theory of Business Enterprise; Absentee Ownership)
-Industry is the technology shared by the community. The industry
produces wealth and is inherently a societal process where every product
embody the entire history of human knowledge. Production goods are only
material means to put the social knowledge to use.
-Business (and economics) is about the creation of pecuniary value and the
capture of earnings.
-Capital is a claim over putative earning-capacity, a claim not on the usufruct of the
past but on future earnings. Capital is only financial capital. 
- Business Earnings cannot be measured by Industrial Productivity. Earnings depend
on the capacity to control the industry.
-- Tangible assets are capitalized in terms of Sabotage capacity; Industry is an 
interdependant concatenated system, by capturing the strategic material means to put 
social knowledge to use, businessmen thus take the industry hostage and can reclaim a 
ransom according to its potential damage capacity. 
- The bulk of any corporation’s capitalization is made of intangible assets, which are 
any durable earning-capacity (due to any institutional setting, like habits of thought, 
legislations, monopoly power or state power).
Power Theory of Capital
Veblen’s Contribution II: Accumulation and Power
(Theory of Business Enterprise; Absentee Ownership)
• Capital Accumulation is process of growing control of Businessmen 
over the Community by implementing institutions (habits of thought) 
serving the interests of businessmen, increasing their earning-capacity.
• In the words of Bichler and Nitzan, from this point of view
accumulation of capital becomes accumulation of power. Capital is
power expressed in monetary terms.
• Not only productive assets are capitalized, but any institutional reality
(social, legal, political, cultural, technical) that can grant an earning
capacity.
• But Veblen emphasizes the increasing control of the vested interests
over the « common man » and doesn’t analyze competition and power
distribution between businessmen, which impeded him to  provide a 
general theory of economic power.
Power Theory of Capital;
A General Theory of Capitalist Power:
Bichler and Nitzan’s Differential Accumulation
- Capitalism has to be analyzed as a whole social order, in which accumulation is 
not an offshoot of production, but, rather, the manifestation of a struggle over 
the shaping of the social process between dominant groups and the rest of 
society, as well as between those groups themselves.
- Capitalized Earning-Capacity represents a claim, not for a share of the output, 
but for a share of control over the social process. Capital is the commodification
of capitalist power and thus capital accumulation is an accumulation of power.
- Power needs to be measured in differential terms. In the capitalist logic, the
aim is not to maximize profit, it to maximize profits compared to others, it is to 
beat the average.
- Capital Accumulation should thus be measured in differential terms
(Differential accumulation) by comparing a group’s (or corporation’s) combined 
capitalization to that of an average unit of capital.
Power Theory of Capital;
Structural Competition
Capitalist Control can be direct: for example, the massive resort to 
advertising to manipulate desires and habits or the killing of competition
through consolidation (M&A’s).
Capitalist Control is mostly structural, it rests on social structures, institutions 
and habits of thought. (Microsoft’s earning-capacity rests on the legitimacy
of intellectual property in the public mind). Capitalist competition should be
understood as a competition to produce and reproduce the institutional
structures serving best the interests of dominant groups (eg: economic
policies, protectionnism, rules included in FTAs, margins of action for 
dominant groups, costs externalization, monopoly power etc.)
Competition becomes structural.
•Market Competition: Competition by lowering prices.
•Monopolistic Competition: Competition by differentiating products.
•Structural Competition: Competition by transforming institutional structures.
Structures of the Global Pharmaceutical Business:
US Share in World Pharmaceutical
Sales: 42%
R&D: 49%
Production: 33%
Source: IMS, EFPIA, OECD Health Data.
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Big Pharma Differential Accumulation; 
Profits of an average US dominant pharmaceutical firm as compared to an 
average Fortune 500 firm (1954-2005; in millions of constant 1984 US$)
Source: Fortune 
Are We Entering a New Era of Innovation?
Breadth in Pharma Differential Accumulation
BUY-TO-BUILD RATIO
Mergers and Acquisitions in proportion to Gross Capital Formation for US 
Pharmaceuticals and All US Sectors, 1981-2003  (log scale)
Sources: -Bichler and Nitzan (2002)
-for all sectors: BEA and Statistical Abstract of the United States
-for pharmaceuticals: OECD Health Data 2006, Thomson Financial
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Breadth in Pharma Differential Accumulation:
How to Interpret the Result
• Betwen 1981 and 2003, M&As represent 403% of Gross Fix Capital Formation for 
Pharmaceuticals; 67% for all firms (which is already historically very high).
• Growing Breadth due mostly to M&As explains in great part the Positive 
Differential Accumulation (positive power accumulation) by US pharmaceutical
firms.
• What does it mean? Our suggested interpretation:
– Movement of Consolidation between pharmaceutical firms in an era of globalization.
– Important barriers to entry, newcomers needs alliance with Big Pharma:
• Patent Thickets (Ownership of Basic Pharmaceutical Knowledge)
• Prohibitive Prices of clinical trials
• Control over distribution network through massive marketing (27% of sales; 65 000$/doctor)
– Pharmaceutical Innovation is not only the result of the corporate realm (Universities, 
National Research Centers, Public Subsidies) but since the Bayh-Dole Act in 1980, 
universities have a great incentive to patent their findings and create start-ups without
any possibility to market their discovery without an alliance with Big Pharma. 
– Big Pharma are marketing machine that managed to externalize R&D in social 
networks of production and control the market by buying back any promising enterprise.
Depth in Pharma Differential Accumulation
Differential Net Returns on Revenues (ROR) Between Big Pharma 
and Fortune 500, 1954-2005
Source: Fortune Magazine
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Depth in Pharma Differential Accumulation:
How to Interpret the Result?
• Returns on Revenues for all firms goes from 5 to 7%  from 1981 to 2005 while
for Big Pharma it goes from 8.5 to 17.5%.
• Establisment of a new Intellectual Property Rights Regime in the 1980s as a 
reaction to declining competitiveness in the United States (Revival of generics, 
U.S. World market share for pharma production from 35.1% in 1970 to 25.9% in 
1980).  
• Series of legislations to promote investments in R&D by increasing R&D 
profits: 
– Extension of intellectual Property Rights
– Tax reductions for R&D
– Restraining other countries from « Stealing from the American Mind ».
Selected Legislations Enabling higher returns on R&D
Agreement on Trade-Related Intellectual Property (TRIPs)1994
National Cooperative Research and Production Act;
North American Free Trade Agreement
1993
Omnibus Trade and Competitiveness Act (Special 301)1988
Federal Technology Transfer Act; 
Drug Export Amendments Act
1986
National Cooperative Research Act;
Drug Price Competition and Patent Term Restoration Act
1984
Orphan Drug Act1983
Small Business Innovation Development Act; 
Court of Appeals for the Federal Circuit
1982
Economic Recovery Act1981
Stevenson-Wydler Innovation Act;  
Bayh-Dole Act
1980
Conclusion
• Positive Differential Accumulation for dominant US Pharmaceutical Business 
means that they those groups are accumulating social power.
• The Differential Accumulation is the result of structural competition, re-shaping
the social process to increase the earning-capacity of dominant firms.
• We saw that Big Pharma had important barriers to entry and that differential
accumulation was due in terms of breadth and depth:
• Breadth: M&A’s are the main process to extend breadth. Barriers to entry
allowed the possibility to externalize R&D where dominant firms buy back
promising results from the social networks of production.
• Depth: A series of new policies increased returns on R&D in the 1980s, by 
extending IPR, reducing taxes and restraining others from producing.
•Conclusion: The increasing power of dominant pharma group relies mostly:
– on their capacity to restrain competition with great barriers to entry.
– on structural transformations allowing the externalization of R&D costs.
– on strucutral transformations increasing returns for IPR owners.
